Terumo Corporation

Terumo Corporation

Financial Results for the Third Quarter of
Fiscal Year Ending March 31, 2023 (FY2022)

February 9, 2023

Naoki Muto, Chief Accounting and Financial Officer

PLAY LIST

from the beginning

Financial Results for the ThirdQuarter of Fiscal Year Ending March 31, 2023 (FY2022)
  • Safe Harbor for Forward-Looking Statements and Use of Document
  • Highlights
  • P&L Results
  • Operating Profit Variance Analysis (Q3)
  • Operating Profit Variance Analysis (Q3 YTD)
  • Revenue by Region
  • C&V: 6% growth excluding FX. China grew high-single digit Segment profit improved both YoY and QoQ due to FX and expense control
  • TMCS: HCS: Japan demand showing signs of recovery PS: New products added, rapid growth Pricing action in Japan to offset macro environment impact
  • TBCT: Blood centers outside Japan strong, maintaining double-digit growth excluding FX Update for plasma innovation; IDE approval for nomogram ver.2 last weekend
  • Guidance Revision
  • Dividend Guidance Revision
  • New Measures to Raise Corporate Value
Reference
  • Product Pipeline and Major Topics
  • Revenue by Segment and Region
  • Quarterly Trend of Revenue and Operating Profit
  • P&L (QoQ)
  • SG&A (QoQ)
  • SG&A (YoY)
  • Adjusted Operating Profit amount
  • CAPEX, Depreciation and R&D Expenses
  • Cash Flows (Q3 YTD)
  • Cash Flows (Q3)
  • FY22 FX Impact Breakdown (Flow, Stock)
  • Foreign Exchange Sensitivity
@
  • Back
  • Next

Download

  • Financial Results for the Third Quarter of Fiscal Year Ending March 31, 2023 (FY2022)(PDF 1.3 MB)
  • Questionnaire Please answer the questionnair
  • Forward-Looking Statements
    System Requirements
GreenPower
link corporate communications